Benign Prostatic Hyperplasia-associated Free Prostate-specific Antigen Improves Detection of Prostate Cancer in an Artificial Neural Network

Urology

Volumn 74, Issue 4, 2009, Pages 873-877

  Stephan, Carsten ^a   Cammann, Henning ^a   Deger, Serdar ^a   Schrader, Mark ^a   Meyer, Hellmuth A ^a   Miller, Kurt ^a   Lein, Michael ^a,b   Jung, Klaus ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Institute for Urologic Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; ARTIFICIAL NEURAL NETWORK; CANCER DIAGNOSIS; CANCER STAGING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY; TRANSURETHRAL RESECTION;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; NEURAL NETWORKS (COMPUTER); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 70349459448     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.02.054     Document Type: Article

References (27)

1. Lilja H., Ulmert D., and Vickers A.J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 8 (2008) 268-278
2. Postma R., Schroder F.H., van Leenders G.J., et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-section Rotterdam: a comparison of two rounds of screening. Eur Urol 52 (2007) 89-97
3. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350 (2004) 2239-2246
4. Stamey T.A., Caldwell M., McNeal J.E., et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol 172 (2004) 1297-1301
5. Stenman U.H., Leinonen J., Alfthan H., et al. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51 (1991) 222-226
6. Lilja H., Christensson A., Dahlen U., et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 37 (1991) 1618-1625
7. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279 (1998) 1542-1547
8. Sokoll L.J., Wang Y., Feng Z., et al. [-2]Proenzyme prostate specific antigen for prostate cancer detection: a National Cancer Institute Early Detection Research Network validation study. J Urol 180 (2008) 539-543
9. Mikolajczyk S.D., Grauer L.S., Millar L.S., et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 50 (1997) 710-714
10. Mikolajczyk S.D., Millar L.S., Wang T.J., et al. "BPSA", a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 55 (2000) 41-45
11. Mikolajczyk S.D., Marks L.S., Partin A.W., et al. Free prostate-specific antigen in serum is becoming more complex. Urology 59 (2002) 797-802
12. De Angelis G., Rittenhouse H.G., Mikolajczyk S.D., et al. Twenty years of PSA: from prostate antigen to tumor marker. Rev Urol 9 (2007) 113-123
13. Mikolajczyk S.D., Song Y., Wong J.R., et al. Are multiple markers the future of prostate cancer diagnostics?. Clin Biochem 37 (2004) 519-528
14. Stephan C., Jung K., Lein M., et al. PSA and other tissue kallikreins for prostate cancer detection. Eur J Cancer 43 (2007) 1918-1926
15. Mikolajczyk S.D., and Rittenhouse H.G. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio J Med 52 (2003) 86-91
16. Wang T.J., Slawin K.M., Rittenhouse H.G., et al. Benign prostatic hyperplasia-associated prostate-specific antigen (BPSA) shows unique immunoreactivity with anti-PSA monoclonal antibodies. Eur J Biochem 267 (2000) 4040-4045
17. Linton H.J., Marks L.S., Millar L.S., et al. Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem 49 (2003) 253-259
18. Canto E.I., Singh H., Shariat S.F., et al. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology 63 (2004) 905-910
19. Naya Y., Fritsche H.A., Bhadkamkar V.A., et al. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer. Urol Oncol 23 (2005) 16-21
20. de Vries S.H., Raaijmakers R., Blijenberg B.G., et al. Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer. Urology 65 (2005) 926-930
21. Stephan C., Kahrs A.M., Cammann H., et al. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 69 (2009) 198-207
22. Stephan C., Jung K., Soosaipillai A., et al. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. BJU Int 96 (2005) 521-527
23. Stephan C., Cammann H., Semjonow A., et al. Multicenter evaluation of an artificial neural network to increase prostate cancer detection rate and reduce unnecessary biopsies. Clin Chem 48 (2002) 1279-1287
24. Finne P., Finne R., Auvinen A., et al. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer Perceptron network. Urology 56 (2000) 418-422
25. Kairisto V., and Poola A. Software for illustrative presentation of basic clinical characteristics of laboratory tests-GraphROC for Windows. Scand J Clin Lab Invest 55 (1995) 43-60
26. Scaramuzzino D.A., Schulte K., Mack B.N., et al. Five-year stability study of free and total prostate-specific antigen concentrations in serum specimens collected and stored at -70 degrees C or less. Int J Biol Markers 22 (2007) 206-213
27. McShane L.M., Altman D.G., Sauerbrei W., et al. Reporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer 41 (2005) 1690-1696